CA3206883A1 - Multifunctional natural killer (nk) cell engagers binding to nkp46 and cd123 - Google Patents
Multifunctional natural killer (nk) cell engagers binding to nkp46 and cd123Info
- Publication number
- CA3206883A1 CA3206883A1 CA3206883A CA3206883A CA3206883A1 CA 3206883 A1 CA3206883 A1 CA 3206883A1 CA 3206883 A CA3206883 A CA 3206883A CA 3206883 A CA3206883 A CA 3206883A CA 3206883 A1 CA3206883 A1 CA 3206883A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- amino acid
- acid sequence
- cdr
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20306717 | 2020-12-31 | ||
| EP20306717.8 | 2020-12-31 | ||
| US202163256950P | 2021-10-18 | 2021-10-18 | |
| US63/256,950 | 2021-10-18 | ||
| PCT/IB2021/062494 WO2022144836A1 (en) | 2020-12-31 | 2021-12-30 | Multifunctional natural killer (nk) cell engagers binding to nkp46 and cd123 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3206883A1 true CA3206883A1 (en) | 2022-07-07 |
Family
ID=79316794
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3206883A Pending CA3206883A1 (en) | 2020-12-31 | 2021-12-30 | Multifunctional natural killer (nk) cell engagers binding to nkp46 and cd123 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11692039B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4271709A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7623497B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR20250152662A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021414400A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3206883A1 (cg-RX-API-DMAC7.html) |
| CO (1) | CO2023008958A2 (cg-RX-API-DMAC7.html) |
| IL (1) | IL304124A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023007901A (cg-RX-API-DMAC7.html) |
| TW (1) | TWI905354B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022144836A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6840682B2 (ja) * | 2015-06-23 | 2021-03-10 | イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. | 多重特異的抗原結合タンパク質 |
| KR20250152662A (ko) * | 2020-12-31 | 2025-10-23 | 사노피 | NKp46 및 CD123에 결합하는 다기능성 자연살해(NK) 세포 관여자 |
| WO2023227790A1 (en) | 2022-05-27 | 2023-11-30 | Sanofi | Natural killer (nk) cell engagers binding to nkp46 and bcma variants with fc-engineering |
| KR102998144B1 (ko) * | 2023-01-16 | 2026-07-31 | 주식회사 드노보 바이오테라퓨틱스 | 신규한 항-NKp46 항체 및 이의 용도 |
| EP4438614A1 (en) * | 2023-03-31 | 2024-10-02 | Sanofi | Methods for purifying heteromultimeric antibodies |
| WO2024224313A1 (en) * | 2023-04-24 | 2024-10-31 | Sanofi | Use of cd123 nk cell engager for treating aml and related disorders |
| US20250064935A1 (en) * | 2023-07-13 | 2025-02-27 | Sanofi | Natural killer cells and cd123 nk cell engager combination therapy |
| WO2025114919A1 (en) * | 2023-11-28 | 2025-06-05 | Sanofi | Multifunctional natural killer (nk) cell engager combination therapy for treating hematological neoplastic disorders |
| WO2026055280A1 (en) * | 2024-09-04 | 2026-03-12 | Sanofi | Interleukin 2 (il-2) and cd123 nk cell engager combination therapy |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5288931A (en) * | 1991-12-06 | 1994-02-22 | Genentech, Inc. | Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation |
| US6177078B1 (en) | 1995-12-29 | 2001-01-23 | Medvet Science Pty Limited | Monoclonal antibody antagonists to IL-3 |
| US7435549B1 (en) | 1997-11-17 | 2008-10-14 | Micromet Ag | Method of identifying binding site domains that retain the capacity of binding to an epitope |
| JP2002541061A (ja) | 1999-02-08 | 2002-12-03 | メドベット・サイエンス・プロプライエタリー・リミテッド | サイトカイン結合ドメイン |
| EP1161453A4 (en) | 1999-02-08 | 2005-01-05 | Medvet Science Pty Ltd | CYTOKIN-BINDING DOMAIN |
| GB9912350D0 (en) * | 1999-05-26 | 1999-07-28 | European Molecular Biology Lab Embl | Modified cytokine |
| ATE510855T1 (de) | 2000-03-06 | 2011-06-15 | Univ Kentucky Res Found | Verwendung eines antikörpers oder eines immunotoxins, der bzw. das selektiv an cd123 bindet zur beeinträchtigung hämatologischer krebs-vorläuferzellen |
| FI117667B (fi) * | 2001-07-05 | 2007-01-15 | Univ Zuerich | Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä |
| NZ543202A (en) | 2003-05-31 | 2008-04-30 | Micromet Ag | Pharmaceutical composition comprising a bispecific antibody for epcam |
| FR2879605B1 (fr) | 2004-12-16 | 2008-10-17 | Centre Nat Rech Scient Cnrse | Production de formats d'anticorps et applications immunologiques de ces formats |
| JP2011505386A (ja) | 2007-12-06 | 2011-02-24 | シーエスエル、リミテッド | 白血病性幹細胞の阻害方法 |
| PE20150680A1 (es) * | 2008-11-26 | 2015-05-16 | Amgen Inc | Variantes de polipeptidos receptores de activina iib y aplicaciones de estos |
| US20100209341A1 (en) | 2009-02-18 | 2010-08-19 | Csl Limited | Treatment of chronic inflammatory conditions |
| ES2550639T3 (es) | 2009-04-27 | 2015-11-11 | Kyowa Hakko Kirin Co., Ltd. | Anticuerpo anti-IL-3Ralfa para su utilización en el tratamiento de un tumor de la sangre |
| EP2436397B1 (en) | 2009-05-29 | 2017-05-10 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition containing antagonist of egf family ligand as component |
| AU2011217728B2 (en) | 2010-02-17 | 2013-03-14 | Csl Limited | Compositions and methods for targeting type 1 interferon producing cells |
| BR112012031189B1 (pt) | 2010-06-07 | 2021-10-26 | Stepan Company | Composição, composição biocida diluível e método de limpeza de uma superfície dura |
| NZ604510A (en) | 2010-08-17 | 2013-10-25 | Csl Ltd | Dilutable biocidal compositions and methods of use |
| US20130210860A1 (en) | 2010-10-06 | 2013-08-15 | Kowa Co., Ltd. | Prophylactic and/or therapeutic agent against lymphedema |
| WO2012059857A2 (en) | 2010-11-01 | 2012-05-10 | Symphogen A/S | Pan-her antibody composition |
| US9155802B2 (en) | 2010-11-01 | 2015-10-13 | Symphogen A/S | Pan-HER antibody composition |
| US9598499B2 (en) | 2010-12-30 | 2017-03-21 | Institut National De La Santé Et De La Recherche Médicale (Inserm) | Antigen binding formats for use in therapeutic treatments or diagnostic assays |
| WO2012106615A1 (en) * | 2011-02-03 | 2012-08-09 | Xoma Technology Ltd. | Methods and materials for enhancing functional protein expression in bacteria |
| GB201203051D0 (en) * | 2012-02-22 | 2012-04-04 | Ucb Pharma Sa | Biological products |
| US20160046718A1 (en) | 2013-03-14 | 2016-02-18 | Csl Limited | Agents that neutralize il-3 signalling and uses thereof |
| WO2014138805A1 (en) | 2013-03-14 | 2014-09-18 | Csl Limited | Anti il-3r alpha agents and uses thereof |
| UA122479C2 (uk) | 2014-01-24 | 2020-11-25 | Дана-Фарбер Кенсер Інстітьют, Інк. | Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1) |
| TR201910814T4 (tr) | 2014-03-19 | 2019-08-21 | Cellectis | Kanser immünoterapisi için cd123 spesifik kimerik antijen reseptörleri. |
| US11041021B2 (en) * | 2014-05-23 | 2021-06-22 | University Of Florida Research Foundation, Incorporated | Car based immunotherapy |
| LT3148579T (lt) | 2014-05-28 | 2021-05-25 | Agenus Inc. | Anti-gitr antikūnai ir jų panaudojimo būdai |
| EP3158064A1 (en) | 2014-06-17 | 2017-04-26 | Cellectis | Cd123 specific multi-chain chimeric antigen receptor |
| AU2015279321B2 (en) | 2014-06-27 | 2021-03-04 | Innate Pharma, S.A. | Multispecific antigen binding proteins |
| JP6822849B2 (ja) | 2014-06-27 | 2021-01-27 | イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. | 多重特異的NKp46結合タンパク質 |
| CN105367657B (zh) | 2014-08-14 | 2019-09-13 | 上海生物制品研究所有限责任公司 | 抗her3抗体、其制法及其应用 |
| ES2688035T3 (es) | 2014-08-29 | 2018-10-30 | Gemoab Monoclonals Gmbh | Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes |
| DK3189081T3 (da) | 2014-09-05 | 2020-05-04 | Janssen Pharmaceutica Nv | Cd123-bindende midler og anvendelser deraf |
| MX2017006167A (es) | 2014-11-12 | 2018-03-23 | Siamab Therapeutics Inc | Compuestos que interactúan con glicanos y métodos de uso. |
| AR103488A1 (es) | 2015-01-23 | 2017-05-10 | Sanofi Sa | Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123 |
| EP3250602A1 (en) | 2015-01-26 | 2017-12-06 | Cellectis | T cell receptor knock out engineered immune cells, endowed with chimeric antigen receptors binding to cd123 for the treatment of relapsed/refractory acute myeloid lymphoma or blastic plasmacytoid dendritic cell neoplasm |
| TWI787796B (zh) | 2015-05-04 | 2022-12-21 | 美商Cytomx生物製藥公司 | 抗cd71抗體類、可活化之抗cd71抗體類及使用彼等之方法 |
| TW201709932A (zh) | 2015-06-12 | 2017-03-16 | 西雅圖遺傳學公司 | Cd123抗體及其共軛物 |
| CA2990398A1 (en) | 2015-06-23 | 2016-12-29 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates of kinesin spindel protein (ksp) inhibitors with anti-cd123-antibodies |
| JP6840682B2 (ja) | 2015-06-23 | 2021-03-10 | イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. | 多重特異的抗原結合タンパク質 |
| AU2016284871B2 (en) | 2015-06-23 | 2022-09-29 | Innate Pharma | Multispecific NK engager proteins |
| CA2994746A1 (en) | 2015-08-11 | 2017-02-16 | Cellectis | Cells for immunotherapy engineered for targeting cd38 antigen and for cd38 gene inactivation |
| CA3002097A1 (en) | 2015-11-12 | 2017-05-18 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
| WO2017096276A1 (en) | 2015-12-02 | 2017-06-08 | Agenus Inc. | Anti-gitr antibodies and methods of use thereof |
| AU2016364895A1 (en) | 2015-12-02 | 2018-06-07 | Agenus Inc. | Anti-GITR antibodies and methods of use thereof |
| MA43389A (fr) | 2015-12-02 | 2021-05-12 | Agenus Inc | Anticorps anti-ox40 et leurs procédés d'utilisation |
| WO2017096179A1 (en) | 2015-12-02 | 2017-06-08 | Agenus Inc. | Antibodies and methods of use thereof |
| CA3007898A1 (en) | 2015-12-28 | 2017-07-06 | Innate Pharma | Variable regions for nkp46 binding proteins |
| WO2017160954A1 (en) | 2016-03-15 | 2017-09-21 | Seattle Genetics, Inc. | Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors |
| WO2017214433A1 (en) | 2016-06-09 | 2017-12-14 | Seattle Genetics, Inc. | Combinations of pbd-based antibody drug conjugates with flt3 inhibitors |
| TWI790206B (zh) * | 2016-07-18 | 2023-01-21 | 法商賽諾菲公司 | 特異性結合至cd3和cd123的雙特異性抗體樣結合蛋白 |
| EP3713959A1 (en) | 2017-11-21 | 2020-09-30 | Innate Pharma | Multispecific antigen binding proteins |
| KR20210133261A (ko) | 2019-02-26 | 2021-11-05 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Bcma에 결합하는 항원 결합 단백질 |
| KR20250152662A (ko) * | 2020-12-31 | 2025-10-23 | 사노피 | NKp46 및 CD123에 결합하는 다기능성 자연살해(NK) 세포 관여자 |
| CN117321087A (zh) | 2021-03-26 | 2023-12-29 | 先天制药公司 | 包含与细胞因子融合用于nk细胞衔接的nkp46结合位点、癌抗原结合位点的多特异性蛋白质 |
| CN117616050A (zh) | 2021-06-09 | 2024-02-27 | 先天制药公司 | 与nkp46、细胞因子受体、肿瘤抗原和cd16a结合的多特异性蛋白质 |
-
2021
- 2021-12-30 KR KR1020257032805A patent/KR20250152662A/ko active Pending
- 2021-12-30 JP JP2023539973A patent/JP7623497B2/ja active Active
- 2021-12-30 TW TW110149620A patent/TWI905354B/zh active
- 2021-12-30 KR KR1020237025940A patent/KR102868401B1/ko active Active
- 2021-12-30 EP EP21840696.5A patent/EP4271709A1/en active Pending
- 2021-12-30 WO PCT/IB2021/062494 patent/WO2022144836A1/en not_active Ceased
- 2021-12-30 CA CA3206883A patent/CA3206883A1/en active Pending
- 2021-12-30 MX MX2023007901A patent/MX2023007901A/es unknown
- 2021-12-30 AU AU2021414400A patent/AU2021414400A1/en active Pending
- 2021-12-30 US US17/566,142 patent/US11692039B2/en active Active
-
2023
- 2023-04-28 US US18/308,778 patent/US20230416383A1/en active Pending
- 2023-06-28 IL IL304124A patent/IL304124A/en unknown
- 2023-07-05 CO CONC2023/0008958A patent/CO2023008958A2/es unknown
-
2025
- 2025-01-15 JP JP2025005123A patent/JP2025063183A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230127306A (ko) | 2023-08-31 |
| AU2021414400A1 (en) | 2023-08-17 |
| TWI905354B (zh) | 2025-11-21 |
| JP2024501539A (ja) | 2024-01-12 |
| US20230416383A1 (en) | 2023-12-28 |
| MX2023007901A (es) | 2023-07-11 |
| CO2023008958A2 (es) | 2023-08-18 |
| EP4271709A1 (en) | 2023-11-08 |
| AU2021414400A9 (en) | 2024-10-17 |
| TW202241952A (zh) | 2022-11-01 |
| KR20250152662A (ko) | 2025-10-23 |
| KR102868401B1 (ko) | 2025-10-14 |
| JP7623497B2 (ja) | 2025-01-28 |
| US20220213202A1 (en) | 2022-07-07 |
| JP2025063183A (ja) | 2025-04-15 |
| US11692039B2 (en) | 2023-07-04 |
| WO2022144836A1 (en) | 2022-07-07 |
| IL304124A (en) | 2023-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11692039B2 (en) | Multifunctional natural killer (NK) cell engagers binding to NKp46 and CD123 | |
| US20250002601A1 (en) | Multispecific antibodies binding to cd20, nkp46, cd16 and conjugated to il-2 | |
| US20220315663A1 (en) | TRISPECIFIC ANTIBODY TARGETING CD79b, CD20, AND CD3 | |
| KR20190091330A (ko) | 항-sirp-알파 항체 및 그의 사용 방법 | |
| JP2022507295A (ja) | 治療用SIRPα抗体 | |
| CN108495864A (zh) | 抗ror1抗体、ror1×cd3双特异性抗体及其使用方法 | |
| CN115461366B (zh) | 抗ox40抗体及其用途 | |
| JP2022553927A (ja) | Ilt-2阻害剤での癌の処置 | |
| CN120958025A (zh) | 针对含cub结构域的蛋白1(cdcp1)的抗体及其用途 | |
| CN117255807A (zh) | 与NKp46和CD123结合的多功能自然杀伤(NK)细胞接合器 | |
| US20250064935A1 (en) | Natural killer cells and cd123 nk cell engager combination therapy | |
| US12286475B2 (en) | Anti-GPRC5D antibodies and compositions | |
| WO2024251884A1 (en) | Nk cell engager proteins comprising anti-cd20 and ant-nkp46 antibody, linked to il-2 in treatment of r/r b-nhl | |
| US20240084014A1 (en) | Multispecific binding compounds that bind to pd-l1 | |
| WO2022098910A1 (en) | Icos antibodies for treatment of lymphomas | |
| CN116615459A (zh) | 抗cd94抗体和其使用方法 | |
| CN121511253A (zh) | Cd123 nk细胞接合器用于治疗aml和相关障碍的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241111 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241111 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20251222 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251222 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251226 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251226 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260218 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260218 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260219 |